Olivia Farrar in Harvard Magazine:
About 11 percent of U.S. adults—roughly 28 million Americans—are now taking GLP-1 medications for weight loss, according to a recent Gallup poll.
The drugs have transformed conversations around obesity, appetite, and metabolism. Lost in much of the dialogue, however, is how these drugs should fit into a broader approach to physical health and exercise. Separately, as demand surges, new debates have begun to unfold over who should pay and have access—with insurers, employers, and policymakers grappling with whether to cover these medications.
More here.
Enjoying the content on 3QD? Help keep us going by donating now.